Becker Muscular Dystrophy - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Becker Muscular Dystrophy - Pipeline Review, H1 2019’, provides an overview of the Becker Muscular Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy

- The report reviews pipeline therapeutics for Becker Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Becker Muscular Dystrophy therapeutics and enlists all their major and minor projects

- The report assesses Becker Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Becker Muscular Dystrophy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Becker Muscular Dystrophy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Becker Muscular Dystrophy - Companies Involved in Therapeutics Development

Catabasis Pharmaceuticals Inc

Becker Muscular Dystrophy - Companies Involved in Therapeutics Development

Catabasis Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Becker Muscular Dystrophy - Overview

Becker Muscular Dystrophy - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Becker Muscular Dystrophy - Overview

Becker Muscular Dystrophy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Becker Muscular Dystrophy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Becker Muscular Dystrophy - Companies Involved in Therapeutics Development

Catabasis Pharmaceuticals Inc

Italfarmaco SpA

Milo Biotechnology LLC

PTC Therapeutics Inc

ReveraGen BioPharma Inc

Becker Muscular Dystrophy - Drug Profiles

AAV1-Follistatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARM-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ataluren - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edasalonexent - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epicatechin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vamorolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Becker Muscular Dystrophy - Dormant Projects

Becker Muscular Dystrophy - Discontinued Products

Becker Muscular Dystrophy - Product Development Milestones

Featured News & Press Releases

Feb 10, 2016: Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy

Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference

Mar 31, 2015: Cardero Therapeutics Presents at 2015 Muscular Dystrophy Association Scientific Conference

Sep 30, 2014: Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound

May 31, 2013: Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound

Mar 31, 2013: Completed triglyceride trial with Cardero Therapeutics lead compound

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Becker Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Products under ...

List of Tables

Number of Products under Development for Becker Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Becker Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H1 2019

Becker Muscular Dystrophy - Pipeline by Italfarmaco SpA, H1 2019

Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H1 2019

Becker Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H1 2019

Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H1 2019

Becker Muscular Dystrophy - Dormant Projects, H1 2019

Becker Muscular Dystrophy - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Becker Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Becker Muscular Dystrophy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports